Enanta Pharma Q3 2024 Adj EPS $(1.07) Beats $(1.45) Estimate, Sales $18.00M Beat $17.18M Estimate
Portfolio Pulse from Benzinga Newsdesk
Enanta Pharma (NASDAQ:ENTA) reported Q3 2024 adjusted EPS of $(1.07), beating the $(1.45) estimate. Sales were $18.00M, surpassing the $17.18M estimate but down 4.72% from last year's $18.89M.
August 05, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enanta Pharma's Q3 2024 earnings and sales both beat analyst estimates, with EPS at $(1.07) vs. $(1.45) expected and sales at $18.00M vs. $17.18M expected. However, sales decreased by 4.72% compared to the same period last year.
Beating both EPS and sales estimates is a positive indicator for Enanta Pharma, likely leading to a short-term stock price increase. However, the year-over-year sales decline may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100